Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has issued a correction disclosure regarding its pharmaceutical contract manufacturing agreement with F.Hoffmann-La Roche Ltd, extending the contract end date from December 31, 2024, to December 31, 2025, upon the customer’s request.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: (Correction) Single Sales and Supply Contract
- Original Filing Date: January 15, 2021
- Reason for Correction: Change in contract period upon customer request
- Key Correction Items:
- Contract End Date: (Before) December 31, 2024 ➔ (After) December 31, 2025
- Contract Details (As Revised in Filing):
- Contract Classification & Title: Other Sales/Supply Contract (Pharmaceutical Contract Manufacturing Agreement)
- Contract Amount: KRW 605,330,045,000 (USD 550,150,000, applied exchange rate KRW 1,100.30 per USD on initial disclosure date Jan 15, 2021)
- Recent Annual Revenue: KRW 701,591,859,755 (Based on recent annual revenue at initial disclosure)
- Contract Amount to Revenue Ratio: 86.28%
- Counterparty: F.Hoffmann-La Roche Ltd
- Contract Period: June 1, 2020 – December 31, 2025
- Contract Date: December 15, 2021
- Disclosure Postponement Details: Not applicable (-)
- Other Important Details:
- This contract is a definitive drug substance manufacturing agreement under the ‘Major Management Matters Related to Investment Decisions’ disclosed on June 8, 2020.
- The contract amount reflects an increase of USD 146,300,000 from the previously disclosed amount (USD 403,850,000) to USD 550,150,000 due to increased demand from the client.
- The contract end date is subject to change depending on production schedules and contract term revisions.
- Related Disclosures:
- June 08, 2020: Major Management Matters Related to Investment Decisions
- January 15, 2021: Single Sales and Supply Contract
- September 27, 2021 / September 28, 2021 / December 16, 2021: Single Sales and Supply Contract
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Contract Period Extension and Project Execution
This correction disclosure provides notice that the contract period end date for the pharmaceutical contract manufacturing deal with F.Hoffmann-La Roche Ltd has been extended to December 31, 2025, at the client’s request.
Tracking contract execution progress and monitoring potential further updates to contract terms is essential.
Relevant developments can be verified in subsequent official disclosures and periodic filings.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
